Immunity and Infections in the Psychiatric Population

Immunity and COVID Infections in the Psychiatric Population

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04381845

Acronym

COVIDIMMUNOPSY

Enrollment

200

Registered

2020-05-11

Start date

2021-01-10

Completion date

2023-12-10

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID, Psychiatric Disorders

Keywords

COVID infection, psychiatric population

Brief summary

The main objective of this multicenter cohort study is to determine the degree of COVID19 infection immunization of a population of psychiatric patients. The secondary objective of this cohort follow-up is to: 1. Clinically characterize COVID patients who are positive for serological testing 2. Assess the socio-demographic, clinical and psychotropic determinants of a COVID diagnosis 3. Immunologically characterize COVID patients who are positive for serological testing 4. Exploring the links between susceptibility to COVID19 and erythrocytic blood groups

Detailed description

All patients accepting to participate will be included in participating psychiatry services and will have a COVID Serological Test for Inclusion with confirmation at J15 including immune-genetics data. A Comparison of COVID patients versus no COVID patients will be based on a clinical examination (psychiatric, somatic) and blood samples collected at J0 and J15.

Interventions

DIAGNOSTIC_TESTCOVID19 immunization testing

serological COVID19 test with confirmation at J15 during hospitalization

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adult patient * Hospitalized in one of the participating psychiatric wards during the inclusion period * Signed informed consent

Exclusion criteria

* Inability to obtain the consent of the patient or legal representative, if applicable * Patient under safeguard of justice

Design outcomes

Primary

Measure	Time frame	Description
Number of COVID-positive patients	day 15	Number of COVID-positive patients, defined by a positive serological test result by immuno-chromatography at inclusion or at 15 days.

Countries

France

Contacts

Primary ContactFrance GUYOT

france.guyot@aphp.fr0144841751

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026